부산대학교 도서관

Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for patients to benefit when HLA genotypically matched sibling is not available. Virtually all patients have at least one HLA partially matched family member, parent, sibling or child, who is immediately available to serve as a donor. In Panamá, between 2007 and 2014, the chance of finding genotypically identical sibling donor was only 36.7%, for these reasons we started in November 2013 HSCT, according to the protocol development in our Laboratory. Methods HLA phenotyping was performed in all the studies, using 2 different molecular methods. DNA samples were amplified with HLA locus-specific primers, then hybridized to panels of sequence specific oligonucleotide probes (LIFECODES HLA-SSO- Typing kits). Potential family members initially typed at the HLA-A, -B, Cw, DRB1, DQB1, DPB1 loci at intermediate resolution. The family members with IPA/NIMA haplotypes, or IMA/NIPA were then typed at the at high-resolution with ABI 3500 Genetic Analyzer additionally perform KIR genotyping to the donor (LIFECODES KIR Typing Kits), HLA antibody screen (LIFECODES Class I, II ID, LIFECODES LSA Class I, II), LIFECODES Donor Specific antibodies (DSA) and chimerism post-transplant using Promega Powerplex 21. We use HLA Matchmaker for determine epitopes mismatch we keep at −86 °C the serum of the recipient, DNA and HLA glycoproteins of the donor. Results The first HSCT was performed in November 2013, and a total of five another HSCT had been performed. Conclusions Haploidentical provides an opportunity for patients to benefit from HCT when and HLA genotypically sibling is not available. Our protocol presents a better logistic to matched donor and it include the necessary procedure for better selection of the haploidentical. We establish advantages for the haploidentical transplant: 1. Shorter wait time for a stem cell transplant. 2. The stem cell transplant is done in about 2–3 weeks, as opposed to several months with other methods. R. Aguilar: Grant/Research Support; Company/Organization; No. 2. Consultant; Company/Organization; No. 3. Speaker’s Bureau; Company/Organization; No. 4. Scientific/Medical Advisor; Company/Organization; No. 5. Employee; Company/Organization; No. 6. Stock Shareholder; Company/Organization; No. 7. Other (Identify); Company/Organization; NO. [ABSTRACT FROM AUTHOR]